WATKINS GLEN, N.Y. (WETM) – Liam Hickey, 6, is one in a million, so it is only fitting he had a special experience at Watkins Glen International race track. The Hickey family has been through some challenging times. Liam was diagnosed with a rare skeletal disease and has undergone several...
Latest News
Abu Dhabi – A team of researchers at NYU Abu Dhabi, led by Professor Sehamuddin Galadari, has discovered that the tumor suppressor protein Prostate apoptosis response-4 (Par-4) can cause a unique type of cell death called ferroptosis in human glioblastoma – the most common and aggressive type of brain tumor...
New York, NY – A diet that limits meat and dairy but is rich in fruits, vegetables, grains, and nuts is linked to less erectile dysfunction, urinary incontinence, and other common side effects seen in prostate cancer patients, a new study shows. Led by researchers at NYU Grossman School of...
NEW YORK, NY — A surgical team at NYU Langone Health has performed the first fully robotic double lung transplant in the world. The procedure marks a breakthrough in the potential of robotic surgery and minimally invasive patient care, making NYU Langone the new leader in robotic transplant surgery around...
NEW YORK, NY — During development of the digestive system, a complex network of nerves forms around it, creating a “second brain” — the enteric nervous system (ENS) — which controls the movement of food and waste through the gut. But a combination of changes in the molecular letters making up certain...
New York, NY – For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer. But despite causing major disease, these slightly mutated proteins can resemble their normal versions so closely that treatments designed to...
TAIPEI, Taiwan — OBI Pharma, a clinical stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its novel antibody – drug conjugate (ADC) cancer therapy targeting TROP2. OBI plans...
TAIPEI, Taiwan – OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the U.S. FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling...
PRINCETON, N.J. – Oblato, Inc. (the Company), a wholly owned U.S. subsidiary of the Korean biotech company GtreeBNT Co., Ltd., announces that the FDA granted Fast Track Designation of OKN-007, the proprietary drug for Diffuse Intrinsic Pontine Glioma (DIPG). The FDA Fast Track is a process designed to facilitate the development...
Philadelphia, PA – A first-line therapy for obsessive-compulsive disorder (OCD) reshapes connectivity of the brain, according to a new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier. OCD is an anxiety disorder characterized by repetitive thoughts and behaviors that can be disruptive and even disabling. The first-line...